Abstract
Recent advances in biotechnology have allowed to characterise the cellular and humoural components of the living organism in more detail. Thus, cells may be cloned or expanded ex vivo in order to perform adoptive transfer strategies, they can be stimulated to proliferate and to exert specific functions by employing recombinant cytokines or by transfection of optional genes. Under in vitro conditions “physiological” mechanisms can be specifically manipulated by these means; however, the complex network of interactions in vivo is poorly understood so far. The actual gap between in vitro research and in vivo studies still asks for somewhat empirically based approaches that may well be guided by the in vitro results. Both aspects are discussed in the following chapters which deal with recent advances in haematology and immunology that may have considerable impact on tumour therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lindemann A, Herrmann F, Oster W, Haffner G, Meyenburg W, Souza LM, Mertelsmann R: Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989 (74): 2644–2651
Lindemann A, Ganser A, Herrmann F, Frisch J, Seipelt G, Schulz G, Hoelzer D, Mertelsmann R: Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 1991 (9): 2120–2127
Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Groues J, Yagoda A, Fain K,Moore MAS, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988 (June 2 ): 1414–1422
Herrmann F, Schulz G, Kolbe K, Nicolay U, Noack M, Lindemann A, Mertelsmann R: Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte- macrophage colony-stimulating factor. J Clin Oncol 1989 (7):59–69
Brugger W, Bross KJ, Frisch J, Dem P, Weber B, Mertelsmann R, Kanz L: Mobilization of peripheral blood progenitor cells by sequential administration of IL-3 and GM-CSF following polychemotherpy with etoposide, ifosfamide and cisplatin. Blood (in press)
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: The lymphokine activated killer cell phenomenon: Lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982 (155):1823–1841
Lindemann A, Höffken K, Schmidt RE, Diehl V, Kloke O, Gamm H, Hayungs J, Oster W, Böhm M, Kolitz JE, Franks CHR, Herrmann F, Mertelsmann RH: A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother 1989 (28):275–281
Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznal M, Mier J, Sparano J, Fisher RL, Weis G, Margolin K, Aronson FR, Hawkins M, Atkins M: A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991 (9):641–648
Osterwalder B: Clinical studies with interleukin-2. An overview. In: Mertelsmann R (ed) Lymphohaemato- poietic Growth Factors in Cancer Therapy, Vol II. European School of Oncology Monographs 1992 (this issue)
Ljunggren HG, Kärre K: In search of the missing self: MHC molecules and NK cell recognition. Immunology Today 1990 (11):237–244
Singh S, Ross SR, Acena M, Rowley DA, Schreiber H: Stroma is critical for preventing of permitting immunological destruction of antigenic cancer cells. J Exp Med 1992 (175):139–146
Hock H, Dorsch M, Diamantstein T, Blankenstein T: Interleukin 7 induces CD4+ T cell dependent tumor rejection. J Exp Med 1991 (174):1291–1298
Gansbacher, Zier BK, Daniels B, Cronin K, Bannerji R, Gilboa E: Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990 (172):1217–1221
Li W, Diamantstein T, Blankenstein T: Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol Immunol 1990 (27): 1331–1336
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Lindemann, A. (1992). Introduction and Overview. In: Mertelsmann, R. (eds) Lymphohaematopoietic Growth Factors in Cancer Therapy II. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77801-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-77801-8_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77803-2
Online ISBN: 978-3-642-77801-8
eBook Packages: Springer Book Archive